A GHRH receptor experiment and a ghrelin receptor experiment use different biological targets. An intact endocrine system adds feedback that a cell assay may not reproduce. Comparing findings across those levels requires the full method. The shared phrase growth hormone release doesn't eliminate differences in receptor selectivity or the timing of a measured response.
Representative product imagery. Verify the physical label and lot documentation on receipt.
Growth Signaling
CJC-1295 + Ipamorelin
In stock·Ships in 1–2 business days
CJC-1295 and Ipamorelin combined in a balanced 5 mg + 5 mg blend. Each unit is labeled with a traceable lot code and links to its corresponding analytical report.
Select size2 options
Select pack sizeSave 18% on kits
1 × 5 mg + 5 mg$69.99
In stockSelected size 5 mg + 5 mgSC-CJCIPA-010
Transparent volume pricing10-vial peptide kits save 18%.
Secure checkout US & EU dispatch
Research use only acknowledgment required at checkout
Report not published
Compound context
What researchers study
CJC-1295 + ipamorelin is a research blend of materials associated with different growth hormone signaling pathways. The labeled quantity of each constituent belongs in the laboratory record. Before choosing a variant, confirm the exact CJC identity because DAC status changes the comparison. A blend name without that detail is insufficient for interpreting a published experiment.
GHRH analogs and growth hormone secretagogues act through distinct receptor systems. Their convergence on an endocrine endpoint doesn't make the molecules interchangeable. Publications on an individual compound can't establish the behavior of a premixed research vial. The CJC 1295 ipamorelin literature also needs careful separation from commercial descriptions of personal stacks.
Measuring one downstream marker after exposure to a blend cannot identify which constituent contributed to the response. Matched individual compound conditions help answer that question. If the material is supplied at a fixed ratio, changing total concentration changes both exposures together. Use that constraint when deciding whether the blend fits the experimental objective.
Scope limitKeep constituent amounts and CJC DAC status with the lot documentation. This product is limited to research. We don't provide daily administration schedules, muscle growth guarantees or clinical dosing instructions.
Serenity Compounds is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Common laboratory focus
Separate the labeled CJC quantity from the labeled ipamorelin quantity before dividing by final volume. Equal mass concentrations are not necessarily equal molar concentrations. The relevant molecular weight must match the documented material. A worksheet should also preserve the blend ratio so another researcher can distinguish the preparation from a different catalog variant.
DAC refers to a modification associated with prolonged exposure in the CJC-1295 literature. Material marketed without DAC must not automatically inherit those duration findings. Ask for the sequence and modification record when the identity isn't clear. An unresolved identity difference limits interpretation even when both materials are grouped under CJC + ipamorelin in searches.
Quality documentation
Know what your laboratory receives.
Batch records are published for transparency and should be independently reviewed by qualified research personnel.
Current certificateCJC-1295 + Ipamorelin · Report not publishedSee original reportView report
- Tamper-evident packaging
- Lot and SKU traceability
- Independent analytical review
Continue exploring
